Growth hormone deficiency and cardiovascular risk: Do we need additional markers?

Endocrine

Volumn 42, Issue 2, 2012, Pages 240-242

  Gola, M ^a,b   Giustina, A ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Mirandola Hospital   (Italy)

^c Department of Surgery   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GROWTH HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN C;

ARTERIAL WALL THICKNESS; ATHEROMATOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; GROWTH HORMONE DEFICIENCY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 84867405219     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9769-x     Document Type: Review

References (29)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones et al., Executive summary: heart disease and stroke statistics-2011 update. A report from the American Heart Association. Circulation 123(4), e18-e209 (2011)
2. G.K. Hansson, A. Hermansson, The immune system in atherosclerosis. Nat. Immunol. 12, 204-212 (2011)
3. W. Xu, R. Li, S. Zhang, L. Gong, Z. Wang, W. Ren, C. Xia, Q. Li, The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China. Endocrine (2012). doi:10.1007/s12020-012- 9599-x
4. N.P. Kadoglou, G. Fotiadis, Z. Athanasiadou, I. Vitta, S. Lampropoulos, I.S. Vrabas, The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes. Endocrine (2012). doi:10.1007/s12020-012-9650-y
5. C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero et al., Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41, 89-95 (2012)
6. A.S. Bates,W. Van't Hoff, P.J. Jones, R.N. Clayton, The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 81, 1169-1172 (1996)
7. T. Rosen, B.-A. Bengsston, Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285-288 (1990)
8. M. Bondanelli, M.R. Ambrosio, A. Onofri et al., Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J. Clin. Endocrinol. Metab. 91, 3928-3934 (2006)
9. G.A. Laughlin, E. Barrett-Connor, M.H. Criqui et al., The prospective association of serum insulin like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 89, 114-120 (2004)
10. A. Giustina, M. Licini, A.R. Bussi et al., Effects of sex and age on the growth hormone response to galanin in healthy human subjects. J. Clin. Endocrinol. Metab. 76, 1369-1372 (1993)
11. A. Giustina, W.B. Wehrenberg, Influence of thyroid hormones on the regulation of growth hormone secretion. Eur. J. Endocrinol. 133, 646-653 (1995)
12. V. Markussis, S.A. Beshyah, C. Fisher, K.H. Parker, A.N. Nicolaides, D.G. Johnston, Abnormal carotid arterial wall dynamics in symptom free hypopituitary adults. Eur. J. Endocrinol. 136, 157-164 (1997)
13. W.J. Brickman, B.L. Silverman, Cardiovascular effects of growth hormone. Endocrine 12, 153-161 (2000)
14. A. Colao, C. di Somma, R. Pivonello et al., The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J. Clin. Endocrinol. Metab. 87, 1088-1093 (2002)
15. P. Maison, P. Chanson, Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648-2652 (2003)
16. A. Giustina, Does growth hormone replacement therapy improve cardiac function? Nat. Clin. Pract. Endocrinol. Metab. 3, 614-615 (2007)
17. M. Andreassen, J. Frystyk, J. Faber, L.Ø. Kristensen, GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. Eur. J. Endocrinol. 166, 811-819 (2012)
18. M. Gola, S. Bonadonna, M. Doga, A. Giustina, Growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90, 1864-1870 (2005)
19. W. Koenig, M. Sund, M. Frolich, H.G. Fischer, H. Lowel, A. Doring, C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 99, 237-242 (1999)
20. Emerging Risk Factors Collaboration, S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson, R. Collins, J. Danesh, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet 375, 132-140 (2010)
21. G. Sesmilo, B.M. Biller, J. Llevadot et al., Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. 133, 111-122 (2000)
22. G. Sesmilo, K.K. Miller, D. Hayden, A. Klibanski, Inflammatory cardiovascular risk markers in women with hypopituitarism. J. Clin. Endocrinol. Metab. 86, 5774-5781 (2001)
23. L. Li, W. Ren, J. Li et al., Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine (2012). doi:10.1007/s12020-012-9697-9
24. J.L. Beaudeux, L. Burc, F. Imbert-Bismut et al., Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 23, e7-e10 (2003)
25. C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons, A.M. Zeiher, CAPTURE Study Investigators, Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45, 229-237 (2005)
26. C. Joaquin, E. Aguilera, M.L. Granada et al., Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 158(4), 483-490 (2008)
27. D. Deepak, C. Daousi, M. Javadpour, D. Clark, Y. Perry, J. Pinkney, I.A. Macfarlane, The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm. IGF Res. 20, 220-225 (2010)
28. C.C. van Bunderen, I.C. van Nieuwpoort, L.I. Arwert et al., Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J. Clin. Endocrinol. Metab. 96, 3151-3159 (2011)
29. H.J. Schneider, J. Klotsche, H.U. Wittchen, German KIMS board and of the DETECT study et al., Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin. Endocrinol. (Oxf) 75, 825-830 (2011)